
================================================================================
ACQUISITION TARGET WATCHLIST REPORT
================================================================================

Watchlist: Top 17 Targets - 2025-12-07
Description: Algorithmically identified M&A targets
Last Updated: 2025-12-07 09:09:37

SUMMARY STATISTICS
--------------------------------------------------------------------------------
Total Targets: 17
Average M&A Score: 64.6/100
Average Market Cap: $2.18B
Average Deal Probability (12mo): 47.9%
High Probability Targets: 11
Total Estimated Deal Value: $55.54B

TOP 10 TARGETS
--------------------------------------------------------------------------------

#1 - REPL: Replimune Group
    M&A Score: 69.2/100 (Top 100%)
    Therapeutic Area: oncology_adc
    Market Cap: $1.15B
    Deal Probability (12mo): 50%
    Top Acquirer: Daiichi Sankyo
    Deal Value: $1.50B - $2.07B (base: $1.73B) (50% premium)

#2 - PRAX: Praxis Precision Medicines
    M&A Score: 68.0/100 (Top 94%)
    Therapeutic Area: cns_neuropsychiatry
    Market Cap: $1.28B
    Deal Probability (12mo): 59%
    Top Acquirer: AbbVie
    Deal Value: $1.66B - $2.30B (base: $1.92B) (50% premium)

#3 - RLAY: Relay Therapeutics
    M&A Score: 67.3/100 (Top 88%)
    Therapeutic Area: oncology_adc
    Market Cap: $1.85B
    Deal Probability (12mo): 59%
    Top Acquirer: Daiichi Sankyo
    Deal Value: $2.40B - $3.33B (base: $2.77B) (50% premium)

#4 - ANNX: Annexon Biosciences
    M&A Score: 67.2/100 (Top 82%)
    Therapeutic Area: autoimmune
    Market Cap: $0.89B
    Deal Probability (12mo): 59%
    Top Acquirer: Johnson & Johnson
    Deal Value: $1.16B - $1.60B (base: $1.33B) (50% premium)

#5 - AURA: Aura Biosciences
    M&A Score: 66.8/100 (Top 76%)
    Therapeutic Area: radiopharmaceuticals
    Market Cap: $0.72B
    Deal Probability (12mo): 48%
    Top Acquirer: Novartis
    Deal Value: $0.94B - $1.30B (base: $1.09B) (50% premium)

#6 - IGMS: IGM Biosciences
    M&A Score: 66.8/100 (Top 71%)
    Therapeutic Area: oncology_adc
    Market Cap: $0.68B
    Deal Probability (12mo): 63%
    Top Acquirer: Daiichi Sankyo
    Deal Value: $0.88B - $1.22B (base: $1.02B) (50% premium)

#7 - FUSN: Fusion Pharmaceuticals
    M&A Score: 66.3/100 (Top 65%)
    Therapeutic Area: radiopharmaceuticals
    Market Cap: $0.85B
    Deal Probability (12mo): 48%
    Top Acquirer: Novartis
    Deal Value: $1.10B - $1.53B (base: $1.27B) (50% premium)

#8 - TBPH: Theratechnologies
    M&A Score: 66.0/100 (Top 59%)
    Therapeutic Area: rare_disease
    Market Cap: $0.58B
    Deal Probability (12mo): 63%
    Top Acquirer: Sanofi
    Deal Value: $0.75B - $1.04B (base: $0.87B) (50% premium)

#9 - XNCR: Xencor
    M&A Score: 64.8/100 (Top 53%)
    Therapeutic Area: autoimmune
    Market Cap: $1.45B
    Deal Probability (12mo): 37%
    Top Acquirer: Johnson & Johnson
    Deal Value: $1.89B - $2.61B (base: $2.17B) (50% premium)

#10 - ELEV: Elevation Oncology
    M&A Score: 64.8/100 (Top 47%)
    Therapeutic Area: oncology_adc
    Market Cap: $0.62B
    Deal Probability (12mo): 47%
    Top Acquirer: Daiichi Sankyo
    Deal Value: $0.81B - $1.12B (base: $0.93B) (50% premium)

================================================================================
